Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.67 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.67 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.67 |
| ▸ | LCK | P06239 | 2/20 | 0.61 |
| ▸ | TEK | Q02763 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12765717 | 0.87 | SRPK1 (0.78) | MAPTLMNAKDRSRPK2SRPK1 | |
| SCHEMBL3485129 | 0.87 | SRPK1 (0.78) | MAPTLMNAKDRSRPK2SRPK1 | |
| SCHEMBL1110544 | 0.80 | SRPK1 (1.00) | MAPTLMNAKDRSRPK2SRPK1 | |
| SCHEMBL1110476 | 0.80 | SRPK1 (1.00) | MAPTLMNAKDRSRPK2SRPK1 | |
| SCHEMBL3485927 | 0.80 | SRPK1 (1.00) | MAPTLMNAKDRSRPK2SRPK1 | |
| SCHEMBL3485680 | 0.80 | POLB (0.81) | MAPTLMNAKDRSRPK2SRPK1 | |
| SCHEMBL12871543 | 0.80 | MAPT (0.76) | MAPTLMNAKDRSRPK2SRPK1 | |
| SCHEMBL3485234 | 0.80 | KDR (0.71) | MAPTLMNAKDRSRPK2SRPK1 | |
| SCHEMBL3485920 | 0.79 | SRPK1 (0.98) | MAPTLMNAKDRSRPK2SRPK1 | |
| SCHEMBL12871545 | 0.78 | MAPT (0.74) | MAPTLMNAKDRSRPK2SRPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | MAPT 4333/4885LMNA 1675/4885KDR 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.